BioVersys 2025 Results: Strong Growth, FDA‑Cleared Phase‑3 BV100 for Resistant Pneumonia
BioVersys 2025 results: steady revenue, strong cash and FDA clearance for BV100 Phase‑3 trial, propelling its multi‑drug‑resistant pneumonia pipeline forward.
3 minutes to read